Science Explorer Back to mapMap

Most cited papers from Moderna Therapeutics (United States)

What are the most cited papers from Moderna Therapeutics (United States)?

The most cited paper from Moderna Therapeutics (United States) is "Lipid nanoparticles for mRNA delivery" (Xucheng Hou, Tal Z. Zaks, Róbert Langer et al., 2021), with 3,994 citations. Next come "SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness" (1,695) and "Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults" (1,641).

Showing 50 of 60 papers. Every paper with more than 186 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Lipid nanoparticles for mRNA delivery Xucheng Hou, Tal Z. Zaks, Róbert Langer et al. · Nature Reviews Materials ReviewOpen access 10 Aug 2021 3,994
2 SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness Kizzmekia S. Corbett et al. · Nature Open access 5 Aug 2020 1,695
3 Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults Evan J. Anderson et al. · New England Journal of Medicine Open access 29 Sep 2020 1,641
4 Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial Peter B. Gilbert et al. · Science Open access 6 Jan 2022 1,218
5 Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines Kimberly J. Hassett, Kerry E. Benenato, Eric Jacquinet et al. · Molecular Therapy — Nucleic Acids Open access 10 Feb 2019 937
6 Pharmaceutical cocrystals: along the path to improved medicines Naga Kiran Duggirala, Miranda L. Perry, Örn Almarsson et al. · Chemical Communications 3 Nov 2015 935
7 Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study Jeffrey S. Weber et al. · The Lancet 21 Jan 2024 871
8 Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination Alicia T. Widge et al. · New England Journal of Medicine Open access 3 Dec 2020 831
9 A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates Staci Sabnis, E. Sathyajith Kumarasinghe, Timothy Salerno et al. · Molecular Therapy Open access 18 Mar 2018 828
10 Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 Nicole A. Doria‐Rose et al. · New England Journal of Medicine Open access 6 Apr 2021 758
11 Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses Kapil Bahl, Joe J. Senn, Olga Yuzhakov et al. · Molecular Therapy Open access 27 Apr 2017 664
12 A Bivalent Omicron-Containing Booster Vaccine against Covid-19 Spyros Chalkias, Charles Harper, Keith W. Vrbicky et al. · New England Journal of Medicine Open access 16 Sep 2022 659
13 Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants Amarendra Pegu et al. · Science Open access158 authors 12 Aug 2021 605
14 Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA Siddharth Patel, N. Ashwanikumar, Ema Robinson et al. · Nature Communications Open access 20 Feb 2020 591
15 mRNA structure regulates protein expression through changes in functional half-life David Mauger, B. Joseph Cabral, Vladimir Presnyak et al. · Proceedings of the National Academy of Sciences Open access 11 Nov 2019 588
16 Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants Hung Fu Tseng, Bradley K. Ackerson, Yi Luo et al. · Nature Medicine Open access 21 Feb 2022 561
17 Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults Eleanor M. P. Wilson et al. · New England Journal of Medicine Open access 13 Dec 2023 499
18 Human 5′ UTR design and variant effect prediction from a massively parallel translation assay Paul J. Sample, Ban Wang, David W. Reid et al. · Nature Biotechnology Open access Jul 2019 483
19 mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants Kaichun Wu, Anne P. Werner, Juan I. Moliva et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 25 Jan 2021 478
20 Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine Kaichun Wu, Anne P. Werner, Matthew A. Koch et al. · New England Journal of Medicine Open access 17 Feb 2021 472
21 mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials Robert Feldman, Rainard Fuhr, Igor V. Smolenov et al. · Vaccine Open access May 2019 466
22 Applications of single-cell RNA sequencing in drug discovery and development Bram Van de Sande, Joon Sang Lee, Euphemia Mutasa-Gottgens et al. · Nature Reviews Drug Discovery ReviewOpen access 28 Apr 2023 455
23 Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis Angela Choi et al. · Nature Medicine Open access 15 Sep 2021 450
24 mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer Gal Cafri, Jared J. Gartner, Tal Z. Zaks et al. · Journal of Clinical Investigation Open access 4 Oct 2020 429
25 Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses Shirley V. Wang et al. · JAMA Open access 25 Apr 2023 414
26 Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques Frank Liang, Gustaf Lindgren, Ang Lin et al. · Molecular Therapy Open access 14 Aug 2017 407
27 SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination Rolando Pajon et al. · New England Journal of Medicine Open access 26 Jan 2022 395
28 SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines Xiaoying Shen, Haili Tang, Charlene B. McDanal et al. · Cell Host & Microbe Open access 7 Mar 2021 394
29 A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial Raffael Nachbagauer et al. · Nature Medicine 7 Dec 2020 367
30 Impact of lipid nanoparticle size on mRNA vaccine immunogenicity Kimberly J. Hassett, Jaclyn S. Higgins, Angela L. Woods et al. · Journal of Controlled Release Open access 18 May 2021 365
31 Impact of mRNA chemistry and manufacturing process on innate immune activation Jennifer A Nelson, Elizabeth W. Sorensen, Shrutika Mintri et al. · Science Advances Open access 24 Jun 2020 359
32 Novel approaches for vaccine development Makda S. Gebre, Luis A. Brito, Lisa H. Tostanoski et al. · Cell Open access Mar 2021 358
33 Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates Kizzmekia S. Corbett et al. · Science Open access 29 Jul 2021 330
34 Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs Susannah L. Hewitt, Ailin Bai, D. R. Shackleton Bailey et al. · Science Translational Medicine 30 Jan 2019 308
35 Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection Christine I. Wooddell, David B. Rozema, Markus Hoßbach et al. · Molecular Therapy Open access 26 Feb 2013 294
36 Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer Amir Massarweh, Noa Eliakim‐Raz, Amos Stemmer et al. · JAMA Oncology Open access 28 May 2021 290
37 N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density Yuri V. Svitkin, Yi Min Cheng, Tirtha Chakraborty et al. · Nucleic Acids Research Open access 21 Feb 2017 280
38 Prospects for a safe COVID-19 vaccine Barton F. Haynes, Lawrence Corey, PRABHAVATHI B. FERNANDES et al. · Science Translational Medicine 19 Oct 2020 276
39 A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems Meredith Packer, Dipendra Gyawali, Ravikiran Yerabolu et al. · Nature Communications Open access 22 Nov 2021 269
40 Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia An Ding et al. · Cell Reports Open access Dec 2017 266
41 A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development Karen B. Fowler, Jacek Mucha, Monika Neumann et al. · BMC Public Health ReviewOpen access Sep 2022 256
42 Boosting Intracellular Delivery of Lipid Nanoparticle-Encapsulated mRNA Siddharth Patel, N. Ashwanikumar, Emily Robinson et al. · Nano Letters Open access 24 Aug 2017 252
43 An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts Athanasios D. Dousis, Kanchana R. Ravichandran, Elissa M. Hobert et al. · Nature Biotechnology Open access 10 Nov 2022 245
44 A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine Laurence Chu, Roderick A. McPhee, Wenmei Huang et al. · Vaccine Open access 9 Feb 2021 240
45 Encapsulation state of messenger RNA inside lipid nanoparticles Mark L. Brader, Sean J. Williams, Jessica M. Banks et al. · Biophysical Journal Open access 25 Mar 2021 237
46 Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity Shinu A. John, Olga Yuzhakov, Angela L. Woods et al. · Vaccine Open access 15 Feb 2018 237
47 An RNA toolbox for cancer immunotherapy Fernando Pastor, Pedro Berraondo, Iñaki Etxeberría et al. · Nature Reviews Drug Discovery Review 7 Sep 2018 230
48 mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron Matthew Gagné et al. · Cell Open access 25 Mar 2022 229
49 Strategies to reduce the risks of mRNA drug and vaccine toxicity Dimitrios Bitounis, Eric Jacquinet, Maximillian A. Rogers et al. · Nature Reviews Drug Discovery Review 23 Jan 2024 228
50 Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 Xiaoying Shen, Haili Tang, Rolando Pajón et al. · New England Journal of Medicine Open access 7 Apr 2021 226

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.